TETRA Technologies

San Diego, California--(Newsfile Corp. - June 17, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric and inherited mitochondrial diseases, today announced the recent activation of its French clinical site for Thiogenesis' ongoing Phase 2 clinical trial evaluating TTI-0102 in patients with Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes ("MELAS"). The first patient at Angers University Hospital Center ("CHU Angers") was dosed last week, marking a key expansion milestone in the Company's multicenter, randomized, double-blind, placebo-controlled MELAS Phase 2 clinical trial.» Mehr auf newsfilecorp.com

San Diego, California--(Newsfile Corp. - June 12, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, announces that pursuant to the terms of the Company's Omnibus Equity Incentive Plan, on June 11, 2025, the Company's board of directors approved a total grant of 400,000 common share purchase options exercisable at $0.77 to two directors of the Company. The common share purchase options vest 25% every six months following the date of grant and expire on June 11, 2030.» Mehr auf newsfilecorp.com

THE WOODLANDS, Texas , June 12, 2025 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE:TTI) announced that its senior management will be participating in two investor conferences in late June.    J.P. Morgan 2025 Energy, Power, Renewables & Mining Conference Brady Murphy, Chief Executive Officer, and Kurt Hallead, VP of Investor Relations and Treasurer, will be hosting one-on-one meetings with institutional investors on June 24 and 25 at the J.P.» Mehr auf prnewswire.com